Curing Cancer Through Strictly Mechanical Approach: Arllecta Group’s New Research Reveals New Ways for Cancer Treatment.

Led by the founder of the Arllecta Group, Egger Mielberg, the research proposes four new marker biochemical, molecular patterns that can make diagnosing and treating cancer at an early stage possible.

The Arllecta Group launched a 2-year research project called 250 years of youth as part of their medical research efforts to push for a more preventive approach to incurable diseases. In line with the project, the Arllecta Group has been conducting ongoing research for the past three years, focusing on the question of which comes first: longevity or cancer. The founder, Egger Mielberg, led this research. The recent online publication of the study presents a novel approach to early cancer combat.

The organization, with its presence in North America, the Middle East, and European and Asian regions, stands among the leading tech giants. Arllecta Group started to form in 2002 when Egger Mielberg set out to find the right combination for the team to drive tech-powered solutions to the world’s recurring problems. Today, they have a team with expertise and experience of more than a decade in machine learning, artificial intelligence, and mathematical modeling to drive new-age solutions for new-age problems. Their ethos for corporate social responsibility is reflected in their regular commitments to community service.

The conclusions offered in Longevity or Cancer: What’s First? are inferred after extensively examining 10 types of cancers. Researchers at the Arllecta Group found and created at least four new biochemical and molecular patterns that could be used to diagnose cancer early, before it has spread, with a 98.8% chance of success. If what has been achieved in theory can be applied successfully, cancer can be completely curable and in its earliest stages.

For the research, the team leveraged their widely recognized mathematical sense theory, which offers a calculated perspective on treatment. Through the objective lens, the study first reveals that the cancer cells in the body are, in fact, part of the human body. This proposition allows reversing cancer cells to their original, healthier state. Introducing the concept of decarcenogenesis, it uses the framework of reversibility of many organic chemical reactions due to the presence of monomers to support the argument presented.

‘The response has been welcoming. Right now, we only hope that our study will give many researchers and ordinary people hope for the unlimited possibilities of the human mind. We are using technology to improve people’s quality of life. 
— Research Team, Arllecta Group

The study has received a positive response from the medical world, and the team has shown their interest in collaboration for further research.
For more details and information about Arllecta Group, please visit https://www.arllecta.com/. To read more about their longevity project, check out https://www.arllecta.com/research.

The complete research paper is available to read for  free at https://www.researchgate.net/publication/388921588_Longevity_or_Cancer_what’s_first. 
 

Media Contact

Organization: Arllecta Group

Contact Person: Igor Mikhailovskii

Website: https://www.arllecta.com/

Email: mikhailovskii.igor@gmail.com

Country: Singapore

Release Id: 12032525014